S3-Leitlinie „Diagnostik und Therapie des Hepatozellulären Karzinoms“ – Langversion 4.0
Bitzer M, Groß S, Albert J, Blödt S, Boda-Heggemann J, Brunner T, Caspari R, De Toni E, Dombrowski F, Evert M, Follmann M, Freudenberger P, Gani C, Geier A, Gkika E, Götz M, Helmberger T, Hoffmann R, Huppert P, Krug D, Fougère C, Lang H, Langer T, Lenz P, Lüdde T, Mahnken A, Nadalin S, Nguyen H, Nothacker M, Ockenga J, Oldhafer K, Paprottka P, Pereira P, Persigehl T, Plentz R, Pohl J, Recken H, Reimer P, Riemer J, Ritterbusch U, Roeb E, Rüssel J, Schellhaas B, Schirmacher P, Schlitt H, Schmid I, Schuler A, Seehofer D, Sinn M, Stengel A, Steubesand N, Stoll C, Tannapfel A, Taubert A, Tholen R, Trojan J, van Thiel I, Vogel A, Vogl T, Wacker F, Waidmann O, Wedemeyer H, Wege H, Wildner D, Wörns M, Galle P, Malek N
Z GASTROENTEROL. 2024;62(1):e67-e161.

S3-Leitlinie „Diagnostik und Therapie des Hepatozellulären Karzinoms“ – Kurzversion
Groß S, Bitzer M, Albert J, Blödt S, Boda-Heggemann J, Brunner T, Caspari R, De Toni E, Dombrowski F, Evert M, Follmann M, Freudenberger P, Gani C, Geier A, Gkika E, Götz M, Helmberger T, Hoffmann R, Huppert P, Krug D, Fougère C, Lang H, Langer T, Lenz P, Lüdde T, Mahnken A, Nadalin S, Nguyen H, Nothacker M, Ockenga J, Oldhafer K, Paprottka P, Pereira P, Persigehl T, Plentz R, Pohl J, Recken H, Reimer P, Riemer J, Ritterbusch U, Roeb E, Rüssel J, Schellhaas B, Schirmacher P, Schlitt H, Schmid I, Schuler A, Seehofer D, Sinn M, Stengel A, Steubesand N, Stoll C, Tannapfel A, Taubert A, Tholen R, Trojan J, van Thiel I, Vogel A, Vogl T, Wacker F, Waidmann O, Wedemeyer H, Wege H, Wildner D, Wörns M, Galle P, Malek N
Z GASTROENTEROL. 2024;62(1):73-109.

A Multimodal Lifestyle Psychosocial Survivorship Program in Young Cancer Survivors: The CARE for CAYA Program-A Randomized Clinical Trial Embedded in a Longitudinal Cohort Study
von Grundherr J, Elmers S, Koch B, Hail L, Mann J, Escherich G, Bergelt C, Samland L, Jensen W, Vettorazzi E, Stark M, Valentini L, Baumann F, Singer S, Reer R, Beller R, Calaminus G, Faber J, Classen C, Gebauer J, Hilgendorf I, Koehler M, Puzik A, Salzmann N, Sander A, Schiffmann L, Sokalska-Duhme M, Schuster S, Kock-Schoppenhauer A, Bokemeyer C, Sinn M, Stein A, Dwinger S, Salchow J
JAMA NETW OPEN. 2024;7(3):e242375.

S3-Leitlinie Diagnostik und Therapie biliärer Karzinome: Kurzversion
Bitzer M, Groß S, Albert J, Boda-Heggemann J, Brunner T, Caspari R, De Toni E, Dombrowski F, Evert M, Geier A, Gkika E, Götz M, Helmberger T, Hoffmann R, Huppert P, Kautz A, Krug D, Fougère C, Lang H, Lenz P, Lüdde T, Mahnken A, Nadalin S, Nguyen H, Ockenga J, Oldhafer K, Paprottka P, Pereira P, Persigehl T, Plentz R, Pohl J, Recken H, Reimer P, Riemer J, Ritterbusch U, Roeb E, Rüssel J, Schellhaas B, Schirmacher P, Schlitt H, Schmid I, Schuler A, Seehofer D, Sinn M, Stengel A, Stoll C, Tannapfel A, Taubert A, Tholen R, Trojan J, van Thiel I, Vogel A, Vogl T, Wacker F, Waidmann O, Wedemeyer H, Wege H, Wildner D, Wörns M, Galle P, Malek N
Z GASTROENTEROL. 2023;61(4):420-440.

S3-Leitlinie Diagnostik und Therapie biliärer Karzinome – Langversion
Bitzer M, Groß S, Albert J, Boda-Heggemann J, Brunner T, Caspari R, De Toni E, Dombrowski F, Evert M, Geier A, Gkika E, Götz M, Helmberger T, Hoffmann R, Huppert P, Kautz A, Krug D, Fougère C, Lang H, Lenz P, Lüdde T, Mahnken A, Nadalin S, Nguyen H, Ockenga J, Oldhafer K, Paprottka P, Pereira P, Persigehl T, Plentz R, Pohl J, Recken H, Reimer P, Riemer J, Ritterbusch U, Roeb E, Rüssel J, Schellhaas B, Schirmacher P, Schlitt H, Schmid I, Schuler A, Seehofer D, Sinn M, Stengel A, Stoll C, Tannapfel A, Taubert A, Tholen R, Trojan J, van Thiel I, Vogel A, Vogl T, Wacker F, Waidmann O, Wedemeyer H, Wege H, Wildner D, Wörns M, Galle P, Malek N
Z GASTROENTEROL. 2023;61(4):e92-e156.

Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline
Falanga A, Ay C, Di Nisio M, Gerotziafas G, Jara-Palomares L, Langer F, Lecumberri R, Mandala M, Maraveyas A, Pabinger I, Sinn M, Syrigos K, Young A, Jordan K
ANN ONCOL. 2023;34(5):452-467.

Peripheral and Portal Venous KRAS ctDNA Detection as Independent Prognostic Markers of Early Tumor Recurrence in Pancreatic Ductal Adenocarcinoma
Nitschke C, Markmann B, Walter P, Badbaran A, Tölle M, Kropidlowski J, Belloum Y, Goetz M, Bardenhagen J, Stern L, Tintelnot J, Schönlein M, Sinn M, van der Leest P, Simon R, Heumann A, Izbicki J, Pantel K, Wikman H, Uzunoglu F
CLIN CHEM. 2023;69(3):295-307.

Effects of Exercise Training on Patient-Specific Outcomes in Pancreatic Cancer Patients: A Scoping Review
Rosebrock K, Sinn M, Uzunoglu F, Bokemeyer C, Jensen W, Salchow J
CANCERS. 2023;15(24):.

Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer
Tintelnot J, Xu Y, Lesker T, Schönlein M, Konczalla L, Giannou A, Pelczar P, Kylies D, Puelles V, Bielecka A, Peschka M, Cortesi F, Riecken K, Jung M, Amend L, Bröring T, Trajkovic-Arsic M, Siveke J, Renné T, Zhang D, Boeck S, Strowig T, Uzunoglu F, Güngör C, Stein A, Izbicki J, Bokemeyer C, Sinn M, Kimmelman A, Huber S, Gagliani N
NATURE. 2023;615(7950):168-174.

S3-Leitlinie: Diagnostik und Therapie biliärer Karzinome: Langversion 2.0 – Juni 2021 – AWMF-Registernummer: 032-053OL
Bitzer M, Voesch S, Albert J, Bartenstein P, Bechstein W, Blödt S, Brunner T, Dombrowski F, Evert M, Follmann M, La Fougère C, Freudenberger P, Geier A, Gkika E, Götz M, Hammes E, Helmberger T, Hoffmann R, Hofmann W, Huppert P, Kautz A, Knötgen G, Körber J, Krug D, Lammert F, Lang H, Langer T, Lenz P, Mahnken A, Meining A, Micke O, Nadalin S, Nguyen H, Ockenga J, Oldhafer K, Paprottka P, Paradies K, Pereira P, Persigehl T, Plauth M, Plentz R, Pohl J, Riemer J, Reimer P, Ringwald J, Ritterbusch U, Roeb E, Schellhaas B, Schirmacher P, Schmid I, Schuler A, von Schweinitz D, Seehofer D, Sinn M, Stein A, Stengel A, Steubesand N, Stoll C, Tannapfel A, Taubert A, Trojan J, van Thiel I, Tholen R, Vogel A, Vogl T, Vorwerk H, Wacker F, Waidmann O, Wedemeyer H, Wege H, Wildner D, Wittekind C, Wörns M, Galle P, Malek N
Z GASTROENTEROL. 2022;60(2):219-238.

Progranulin mediates immune evasion of pancreatic ductal adenocarcinoma through regulation of MHCI expression
Cheung P, Yang J, Fang R, Borgers A, Krengel K, Stoffel A, Althoff K, Yip C, Siu E, Ng L, Lang K, Cham L, Engel D, Soun C, Cima I, Scheffler B, Striefler J, Sinn M, Bahra M, Pelzer U, Oettle H, Markus P, Smeets E, Aarntzen E, Savvatakis K, Liffers S, Lueong S, Neander C, Bazarna A, Zhang X, Paschen A, Crawford H, Chan A, Cheung S, Siveke J
NAT COMMUN. 2022;13(1):.

Tumor-Stroma Interaction in PDAC as a New Approach for Liquid Biopsy and its Potential Clinical Implications
Götze J, Nitschke C, Uzunoglu F, Pantel K, Sinn M, Wikman H
FRONT CELL DEV BIOL. 2022;10:.

Situation klinischer Studien in Deutschland – ein interdisziplinäres Positionspapier
Grünwald V, Bethge W, Blohmer J, Burkhardt B, Dirksen U, Ebert M, Gschwend J, Gutzmer R, Henn D, Hermann K, Isbary G, Klußmann J, Knauf W, Krause M, Luntz S, Paradies K, Piso P, Ryll B, Schmidt G, Sinn M, Stintzing S, Wedding U, Wesselmann S, Reinacher-Schick A
ONKOLOGE. 2022;28(Suppl 1):19-22.

Multimodal survival prediction in advanced pancreatic cancer using machine learning
Keyl J, Kasper S, Wiesweg M, Götze J, Schönrock M, Sinn M, Berger A, Nasca E, Kostbade K, Schumacher B, Markus P, Albers D, Treckmann J, Schmid K, Schildhaus H, Siveke J, Schuler M, Kleesiek J
ESMO OPEN. 2022;7(5):.

Anticoagulation Practice in Patients with Cancer-Associated Thrombosis: Insights from GeCAT, a German Prospective Registry Study
Klamroth R, Sinn M, Pollich C, Bischoff S, Lohneis A, Orlovic A, Wislocka L, Habbel P, de Wit M, Späth-Schwalbe E, Scholz C, Riess H
ONCOL RES TREAT. 2022;45(4):178-185.

Circulating Cancer Associated Macrophage-like Cells as a Potential New Prognostic Marker in Pancreatic Ductal Adenocarcinoma
Nitschke C, Markmann B, Konczalla L, Kropidlowski J, Pereira-Veiga T, Scognamiglio P, Schönrock M, Sinn M, Tölle M, Izbicki J, Pantel K, Uzunoglu F, Wikman H
BIOMEDICINES. 2022;10(11):.

Characterization of RARRES1 Expression on Circulating Tumor Cells as Unfavorable Prognostic Marker in Resected Pancreatic Ductal Adenocarcinoma Patients
Nitschke C, Markmann B, Tölle M, Kropidlowski J, Belloum Y, Goetz M, Schlüter H, Kwiatkowski M, Sinn M, Izbicki J, Pantel K, Güngör C, Uzunoglu F, Wikman H
CANCERS. 2022;14(18):.

Consensus Statement on Mandatory Measurements for Pancreatic Cancer Trials for Patients With Resectable or Borderline Resectable Disease (COMM-PACT-RB): A Systematic Review and Delphi Consensus Statement
Pijnappel E, Suurmeijer J, Koerkamp B, Kos M, Siveke J, Salvia R, Ghaneh P, van Eijck C, van Etten-Jamaludin F, Abrams R, Brasiuniene B, Büchler M, Casadei R, van Laethem J, Berlin J, Boku N, Conroy T, Golcher H, Sinn M, Neoptolemos J, van Tienhoven G, Besselink M, Wilmink J, van Laarhoven H
JAMA ONCOL. 2022;8(6):929-937.

S3-Leitlinie: Diagnostik und Therapie des hepatozellulären Karzinoms
Sabrina V, Michael B, Jörg A, Peter B, Wolf B, Susanne B, Thomas B, Frank D, Matthias E, Markus F, Christian L, Paul F, Andreas G, Eleni G, Martin G, Elke H, Thomas H, Ralf-Thorsten H, Wolf-Peter H, Peter H, Achim K, Gabi K, Jürgen K, David K, Frank L, Hauke L, Thomas L, Philipp L, Andreas M, Alexander M, Oliver M, Silvio N, Huu Phuc N, Johann O, Karl-Jürgen O, Philipp P, Kerstin P, Philippe P, Thorsten P, Mathias P, Ruben P, Jürgen P, Jutta R, Peter R, Johanna R, Ulrike R, Elke R, Barbara S, Peter S, Irene S, Andreas S, Dietrich v, Daniel S, Marianne S, Alexander S, Andreas S, Nadine S, Christian S, Andrea T, Anne T, Jörg T, Ingo v, Reina T, Arndt V, Thomas V, Hilke V, Frank W, Oliver W, Heiner W, Henning W, Dane W, Christian W, Marcus-Alexander W, Peter G, Nisar M
Z GASTROENTEROL. 2022;60(1):e56-e130.

S3-Leitlinie: Diagnostik und Therapie des hepatozellulären Karzinoms – Kurzversion 2.00 – Juni 2021, AWMF-Registernummer: 032-053OL
Sabrina V, Michael B, Jörg A, Peter B, Wolf B, Susanne B, Thomas B, Frank D, Matthias E, Markus F, Christian L, Paul F, Andreas G, Eleni G, Martin G, Elke H, Thomas H, Ralf-Thorsten H, Wolf-Peter H, Peter H, Achim K, Gabi K, Jürgen K, David K, Frank L, Hauke L, Thomas L, Philipp L, Andreas M, Alexander M, Oliver M, Silvio N, Huu Phuc N, Johann O, Karl-Jürgen O, Philipp P, Kerstin P, Philippe P, Thorsten P, Mathias P, Ruben P, Jürgen P, Jutta R, Peter R, Johanna R, Ulrike R, Elke R, Barbara S, Peter S, Irene S, Andreas S, Dietrich v, Daniel S, Marianne S, Alexander S, Andreas S, Nadine S, Christian S, Andrea T, Anne T, Jörg T, Ingo v, Reina T, Arndt V, Thomas V, Hilke V, Frank W, Oliver W, Heiner W, Henning W, Dane W, Christian W, Marcus-Alexander W, Peter G, Nisar M
Z GASTROENTEROL. 2022;60(1):81-107.

Risk factors for poor humoral response to primary and booster SARS-CoV-2 vaccination in hematologic and oncological outpatients-COVIDOUT study
Schönlein M, Wrage V, Ghandili S, Mellinghoff S, Brehm T, Leypoldt L, Utz N, Schrader R, Alsdorf W, Börschel N, Bußmann L, Schönrock M, Perlick D, Schön G, Verpoort K, Lütgehetmann M, Schulze Zur Wiesch J, Weisel K, Bokemeyer C, Schafhausen P, Sinn M
CANCER CELL. 2022;40(6):581-583.

S3-Leitlinie zum exokrinen Pankreaskarzinom – Kurzversion 2.0 – Dezember 2021, AWMF-Registernummer: 032/010OL
Seufferlein T, Mayerle J, Böck S, Brunner T, Ettrich T, Grenacher L, Gress T, Hackert T, Heinemann V, Kestler A, Sinn M, Tannapfel A, Wedding U, Uhl W
Z GASTROENTEROL. 2022;60(6):991-1037.

S3-Leitlinie zum exokrinen Pankreaskarzinom – Langversion 2.0 – Dezember 2021 – AWMF-Registernummer: 032/010OL
Seufferlein T, Mayerle J, Böck S, Brunner T, Ettrich T, Grenacher L, Gress T, Hackert T, Heinemann V, Kestler A, Sinn M, Tannapfel A, Wedding U, Uhl W
Z GASTROENTEROL. 2022;60(11):e812-e909.

Comparison of meniscal T1rho- and T2*-relaxation times in professional female volleyball players and healthy controls using 3T MRI: A pilot study
Spink C, Henes F, Da Cruz L, Sinn M, Behzadi C, Schoen G, Welsch G, Adam G, Bannas P, Maas K
EUR J RADIOL. 2022;155:.

Efficacy of Ipilimumab vs FOLFOX in Combination With Nivolumab and Trastuzumab in Patients With Previously Untreated ERBB2-Positive Esophagogastric Adenocarcinoma: The AIO INTEGA Randomized Clinical Trial
Stein A, Paschold L, Tintelnot J, Goekkurt E, Henkes S, Simnica D, Schultheiss C, Willscher E, Bauer M, Wickenhauser C, Thuss-Patience P, Lorenzen S, Ettrich T, Riera-Knorrenschild J, Jacobasch L, Kretzschmar A, Kubicka S, Al-Batran S, Reinacher-Schick A, Pink D, Sinn M, Lindig U, Hiegl W, Hinke A, Hegewisch-Becker S, Binder M
JAMA ONCOL. 2022;8(8):1150-1158.

Dual Targeting of the EGFR/HER2 Pathway in Combination with Systemic Chemotherapy in Refractory Pancreatic Cancer-The CONKO-008 Phase I Investigation
Striefler J, Stieler J, Neumann C, Geisel D, Ghadjar P, Sinn M, Malinka T, Pratschke J, Stintzing S, Oettle H, Riess H, Pelzer U
J CLIN MED. 2022;11(16):.

Completion of FLOT Therapy, Regardless of Tumor Regression, Significantly Improves Overall Survival in Patients with Esophageal Adenocarcinoma
Stüben B, Stuhlfelder J, Kemper M, Tachezy M, Ghadban T, Izbicki J, Bokemeyer C, Sinn M, Karstens K, Reeh M
CANCERS. 2022;14(4):.

Acceptance and Benefits of Two Different Strategies to Timely Integrate Specialist Palliative Care into Routine Cancer Care - a Randomized Pilot Study
Ullrich A, Wilde S, Müller V, Sinn M, Gebhardt C, Velthaus J, Gerlach C, Bokemeyer C, Oechsle K
ONCOL RES TREAT. 2022;45(3):118-129.

Post-Vaccination Anti-SARS-CoV-2-Antibody Response in Patients with Multiple Myeloma Correlates with Low CD19+ B-Lymphocyte Count and Anti-CD38 Treatment
Ghandili S, Schönlein M, Lütgehetmann M, Wiesch J, Becher H, Bokemeyer C, Sinn M, Weisel K, Leypoldt L
CANCERS. 2021;13(15):.

Lymphocytopenia and Anti-CD38 Directed Treatment Impact the Serological SARS-CoV-2 Response after Prime Boost Vaccination in Patients with Multiple Myeloma
Ghandili S, Schönlein M, Wiessner C, Becher H, Lütgehetmann M, Brehm T, Wiesch J, Bokemeyer C, Sinn M, Weisel K, Leypoldt L
J CLIN MED. 2021;10(23):.

A genetically defined signature of responsiveness to erlotinib in early-stage pancreatic cancer patients: Results from the CONKO-005 trial
Hoyer K, Hablesreiter R, Inoue Y, Yoshida K, Briest F, Christen F, Kakiuchi N, Yoshizato T, Shiozawa Y, Shiraishi Y, Striefler J, Bischoff S, Lohneis P, Putter H, Blau O, Keilholz U, Bullinger L, Pelzer U, Hummel M, Riess H, Ogawa S, Sinn M, Damm F
EBIOMEDICINE. 2021;66:.

Impact of completeness of adjuvant gemcitabine, relapse pattern, and subsequent therapy on outcome of patients with resected pancreatic ductal adenocarcinoma - A pooled analysis of CONKO-001, CONKO-005, and CONKO-006 trials
Kurreck A, Weckwerth J, Modest D, Striefler J, Bahra M, Bischoff S, Pelzer U, Oettle H, Kruger S, Riess H, Sinn M
EUR J CANCER. 2021;150:250-259.

Effects of a structured counselling-based intervention to improve physical activity behaviour of adolescents and young adult cancer survivors - the randomized phase II Motivate AYA - MAYA trial
Salchow J, Koch B, Mann J, von Grundherr J, Elmers S, Dwinger S, Escherich G, Vettorazzi E, Reer R, Sinn M, Baumann F, Bokemeyer C, Stein A, Jensen W
CLIN REHABIL. 2021;35(8):1164-1174.

71/m in reduziertem Allgemeinzustand mit Sklerenikterus
Schönrock M, Sinn M
ONKOLOGE. 2021;2021(27 supplement issue 1):109-113.

Mucin-1 Protein Is a Prognostic Marker for Pancreatic Ductal Adenocarcinoma: Results From the CONKO-001 Study
Striefler J, Riess H, Lohneis P, Bischoff S, Kurreck A, Modest D, Bahra M, Oettle H, Sinn M, Bläker H, Denkert C, Stintzing S, Sinn B, Pelzer U
FRONT ONCOL. 2021;11:.

Efficacy and Safety of CAP7.1 as Second-Line Treatment for Advanced Biliary Tract Cancers: Data from a Randomised Phase II Study
Pape U, Kasper S, Meiler J, Sinn M, Vogel A, Müller L, Burkhard O, Caca K, Heeg S, Büchner-Steudel P, Rodriguez-Laval V, Kühl A, Arsenic R, Jansen H, Treasure P, Utku N
CANCERS. 2020;12(11):.

CONKO-006: A randomised double-blinded phase IIb-study of additive therapy with gemcitabine + sorafenib/placebo in patients with R1 resection of pancreatic cancer - Final results
Sinn M, Liersch T, Riess H, Gellert K, Stübs P, Waldschmidt D, Lammert F, Maschmeyer G, Bechstein W, Bitzer M, Denzlinger C, Hofheinz R, Lindig U, Ghadimi M, Hinke A, Striefler J, Pelzer U, Bischoff S, Bahra M, Oettle H
EUR J CANCER. 2020;138:172-181.

TP53 mutations predict sensitivity to adjuvant gemcitabine in patients with pancreatic ductal adenocarcinoma: next-generation sequencing results from the CONKO-001 trial
Sinn M, Sinn B, Treue D, Keilholz U, Damm F, Schmuck R, Lohneis P, Klauschen F, Striefler J, Bahra M, Bläker H, Bischoff S, Pelzer U, Oettle H, Riess H, Budczies J, Denkert C
CLIN CANCER RES. 2020;26(14):3732-3739.

Gallengangs- und Gallenblasenkarzinome: auf dem Weg zur personalisierten Therapie
Sinn M, Wege H, Stein A
DEUT MED WOCHENSCHR. 2020;145(7):442-446.

Dihydropyrimidine Dehydrogenase Testing prior to Treatment with 5-Fluorouracil, Capecitabine, and Tegafur: A Consensus Paper
Wörmann B, Bokemeyer C, Burmeister T, Köhne C, Schwab M, Arnold D, Blohmer J, Borner M, Brucker S, Cascorbi I, Decker T, de Wit M, Dietz A, Einsele H, Eisterer W, Folprecht G, Hilbe W, Hoffmann J, Knauf W, Kunzmann V, Largiadèr C, Lorenzen S, Lüftner D, Moehler M, Nöthen M, Pox C, Reinacher-Schick A, Scharl A, Schlegelberger B, Seufferlein T, Sinn M, Stroth M, Tamm I, Trümper L, Wilhelm M, Wöll E, Hofheinz R
ONCOL RES TREAT. 2020;43(11):628-636.

Position of Scientific Oncological Societies Towards Biosimilar Antibodies
Wörmann B, Sinn M
BREAST CARE. 2019;14(1):5-8.

Hematopoietic lineage distribution and evolutionary dynamics of clonal hematopoiesis
Arends C, Galan-Sousa J, Hoyer K, Chan W, Jäger M, Yoshida K, Seemann R, Noerenberg D, Waldhueter N, Fleischer-Notter H, Christen F, Schmitt C, Dörken B, Pelzer U, Sinn M, Zemojtel T, Ogawa S, Märdian S, Schreiber A, Kunitz A, Krüger U, Bullinger L, Mylonas E, Frick M, Damm F
LEUKEMIA. 2018;32(9):1908-1919.

Two patients with rare mixed adenoneuroendocrine carcinomas of the rectum
Gül-Klein S, Sinn M, Jurmeister P, Biebl M, Weiß S, Rau B, Bläker H, Pratschke J, Aigner F
SAGE OPEN MED CASE R. 2018;6:2050313X18758816.

Tumour buds determine prognosis in resected pancreatic ductal adenocarcinoma
Lohneis P, Sinn M, Klein F, Bischoff S, Striefler J, Wislocka L, Sinn B, Pelzer U, Oettle H, Riess H, Denkert C, Bläker H, Jühling A
BRIT J CANCER. 2018;118(11):1485-1491.

Safety and efficacy of Nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer suffering from cholestatic hyperbilirubinaemia-A retrospective analysis
Pelzer U, Wislocka L, Jühling A, Striefler J, Klein F, Roemmler-Zehrer J, Sinn M, Denecke T, Bahra M, Riess H
EUR J CANCER. 2018;100:85-93.

PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer-a randomised biomarker-driven clinical phase II AIO study
Vogel A, Kasper S, Bitzer M, Block A, Sinn M, Schulze-Bergkamen H, Moehler M, Pfarr N, Endris V, Goeppert B, Merx K, Schnoy E, Siveke J, Michl P, Waldschmidt D, Kuhlmann J, Geissler M, Kahl C, Evenkamp R, Schmidt T, Kuhlmann A, Weichert W, Kubicka S
EUR J CANCER. 2018;92:11-19.

Incidence and Oncological Implications of Previously Undetected Tumor Multicentricity Following Pancreaticoduodenectomy for Pancreatic Adenocarcinoma in Patients Undergoing Salvage Pancreatectomy
Andreou A, Klein F, Schmuck R, Lee D, Sinn M, Denecke T, Pratschke J, Bahra M
ANTICANCER RES. 2017;37(9):5269-5275.

Hepatotoxicity following systemic therapy for colorectal liver metastases and the impact of chemotherapy-associated liver injury on outcomes after curative liver resection
Duwe G, Knitter S, Pesthy S, Beierle A, Bahra M, Schmelzle M, Schmuck R, Lohneis P, Raschzok N, Öllinger R, Sinn M, Struecker B, Sauer I, Pratschke J, Andreou A
EJSO-EUR J SURG ONC. 2017;43(9):1668-1681.

Cytotoxic tumour-infiltrating T lymphocytes influence outcome in resected pancreatic ductal adenocarcinoma
Lohneis P, Sinn M, Bischoff S, Jühling A, Pelzer U, Wislocka L, Bahra M, Sinn B, Denkert C, Oettle H, Bläker H, Riess H, Jöhrens K, Striefler J
EUR J CANCER. 2017;83:290-301.

Risk estimation for biliary tract cancer: Development and validation of a prognostic score
Schweitzer N, Fischer M, Kirstein M, Berhane S, Kottas M, Sinn M, Gonzalez-Carmona M, Balta Z, Weismüller T, Strassburg C, Reineke-Plaaß T, Bektas H, Manns M, Johnson P, Weinmann A, Vogel A
LIVER INT. 2017;37(12):1852-1860.

CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial
Sinn M, Bahra M, Liersch T, Gellert K, Messmann H, Bechstein W, Waldschmidt D, Jacobasch L, Wilhelm M, Rau B, Grützmann R, Weinmann A, Maschmeyer G, Pelzer U, Stieler J, Striefler J, Ghadimi M, Bischoff S, Dörken B, Oettle H, Riess H
J CLIN ONCOL. 2017;35(29):3330-3337.

SPARC expression in resected pancreatic cancer patients treated with Gemcitabine: results from the CONKO-001 study
Sinn M, Sinn B, Striefler J, Lindner J, Stieler J, Lohneis P, Bischoff S, Bläker H, Pelzer U, Bahra M, Dietel M, Dörken B, Oettle H, Riess H, Denkert C
ANN ONCOL. 2017;28(11):2900.

Dose-escalated radiotherapy for unresectable or locally recurrent pancreatic cancer: Dose volume analysis, toxicity and outcome of 28 consecutive patients
Zschaeck S, Blümke B, Wust P, Kaul D, Bahra M, Riess H, Klein F, Sinn M, Pelzer U, Budach V, Ghadjar P
PLOS ONE. 2017;12(10):e0186341.

Resting heart rate is an independent predictor of death in patients with colorectal, pancreatic, and non-small cell lung cancer: results of a prospective cardiovascular long-term study
Anker M, Ebner N, Hildebrandt B, Springer J, Sinn M, Riess H, Anker S, Landmesser U, Haverkamp W, von Haehling S
EUR J HEART FAIL. 2016;18(12):1524-1534.

Primary prevention and treatment of venous thromboembolic events in patients with gastrointestinal cancers - Review
Riess H, Habbel P, Jühling A, Sinn M, Pelzer U
WORLD J GASTRO ONCOL. 2016;8(3):258-70.

Perioperative treatment options in resectable pancreatic cancer - how to improve long-term survival
Sinn M, Bahra M, Denecke T, Travis S, Pelzer U, Riess H
WORLD J GASTRO ONCOL. 2016;8(3):248-57.

Second-Line Treatment in Pancreatic Cancer Patients: Who Profits?--Results From the CONKO Study Group
Sinn M, Dälken L, Striefler J, Bischoff S, Schweitzer N, Pelzer U, Dörken B, Riess H, Stieler J
PANCREAS. 2016;45(4):601-5.

P53 overexpression and Ki67-index are associated with outcome in ductal pancreatic adenocarcinoma with adjuvant gemcitabine treatment
Striefler J, Sinn M, Pelzer U, Jühling A, Wislocka L, Bahra M, Sinn B, Denkert C, Dörken B, Oettle H, Riess H, Bläker H, Lohneis P
PATHOL RES PRACT. 2016;212(8):726-34.

Einsatz von Neuen oralen Antikoagulanzien (NOAK) bei onkologischen Patienten
Trappe R, Sinn M, Riess H
DEUT MED WOCHENSCHR. 2016;141(20):1446-1450.

Cytoreductive Surgery for Pancreatic Cancer Improves Overall Outcome of Gemcitabine-Based Chemotherapy
Bahra M, Pratschke J, Klein F, Neuhaus P, Boas-Knoop S, Puhl G, Denecke T, Pullankavumkal J, Sinn M, Riess H, Pelzer U
PANCREAS. 2015;44(6):930-6.

Prognostic significance of DNA cytometry for adjuvant therapy response in pancreatic cancer
Klein F, Bahra M, Schirmeier A, Al-Abadi H, Pratschke J, Pelzer U, Oettle H, Striefler J, Riess H, Sinn M
J SURG ONCOL. 2015;112(1):66-71.

Efficacy of Prophylactic Low-Molecular Weight Heparin for Ambulatory Patients With Advanced Pancreatic Cancer: Outcomes From the CONKO-004 Trial
Pelzer U, Opitz B, Deutschinoff G, Stauch M, Reitzig P, Hahnfeld S, Müller L, Grunewald M, Stieler J, Sinn M, Denecke T, Bischoff S, Oettle H, Dörken B, Riess H
J CLIN ONCOL. 2015;33(18):2028-34.

Human equilibrative nucleoside transporter 1 expression analysed by the clone SP 120 rabbit antibody is not predictive in patients with pancreatic cancer treated with adjuvant gemcitabine - Results from the CONKO-001 trial
Sinn M, Riess H, Sinn B, Stieler J, Pelzer U, Striefler J, Oettle H, Bahra M, Denkert C, Bläker H, Lohneis P
EUR J CANCER. 2015;51(12):1546-54.

Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial: outcomes from the CONKO-003 trial
Oettle H, Riess H, Stieler J, Heil G, Schwaner I, Seraphin J, Görner M, Mölle M, Greten T, Lakner V, Bischoff S, Sinn M, Dörken B, Pelzer U
J CLIN ONCOL. 2014;32(23):2423-9.

Intensified chemotherapy and simultaneous treatment with heparin in outpatients with pancreatic cancer - the CONKO 004 pilot trial
Pelzer U, Hilbig A, Stieler J, Bahra M, Sinn M, Gebauer B, Dörken B, Riess H
BMC CANCER. 2014;14:204.

Multimodale Therapie des Pankreaskarzinoms
Pelzer U, Sinn M, Stieler J, Riess H
INTERNIST. 2014;55(1):31-6.

KRAS mutations in codon 12 or 13 are associated with worse prognosis in pancreatic ductal adenocarcinoma
Sinn B, Striefler J, Rudl M, Lehmann A, Bahra M, Denkert C, Sinn M, Stieler J, Klauschen F, Budczies J, Weichert W, Stenzinger A, Kamphues C, Dietel M, Riess H
PANCREAS. 2014;43(4):578-83.

α-Smooth muscle actin expression and desmoplastic stromal reaction in pancreatic cancer: results from the CONKO-001 study
Sinn M, Denkert C, Striefler J, Pelzer U, Stieler J, Bahra M, Lohneis P, Dörken B, Oettle H, Riess H, Sinn B
BRIT J CANCER. 2014;111(10):1917-23.

Intensity-modulated and image-guided radiotherapy in patients with locally advanced inoperable pancreatic cancer after preradiation chemotherapy
Sinn M, Ganeshan R, Graf R, Pelzer U, Stieler J, Striefler J, Bahra M, Wust P, Riess H
SCI WORLD J. 2014;2014:452089.

Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: Results from the CONKO-001 study
Oettle H, Neuhaus P, Hochhaus A, Hartmann J, Gellert K, Ridwelski K, Niedergethmann M, Zülke C, Fahlke J, Arning M, Sinn M, Hinke A, Riess H
JAMA-J AM MED ASSOC. 2013;310(14):1473-81.

Value of carbohydrate antigen 19-9 in predicting response and therapy control in patients with metastatic pancreatic cancer undergoing first-line therapy
Pelzer U, Hilbig A, Sinn M, Stieler J, Bahra M, Dörken B, Riess H
FRONT ONCOL. 2013;3:155.

Blood group determinates incidence for pancreatic cancer in Germany
Pelzer U, Klein F, Bahra M, Sinn M, Dörken B, Neuhaus P, Meyer O, Riess H
FRONT PHYSIOL. 2013;4:118.

Primäre medikamentöse Thromboembolieprophylaxe bei ambulanten Patienten mit fortgeschrittenem Pankreaskarzinom unter Chemotherapie?
Pelzer U, Sinn M, Stieler J, Riess H
DEUT MED WOCHENSCHR. 2013;138(41):2084-8.

Hepatic arterial infusion with oxaliplatin and 5-FU/folinic acid for advanced biliary tract cancer: a phase II study
Sinn M, Nicolaou A, Gebauer B, Podrabsky P, Seehofer D, Ricke J, Dörken B, Riess H, Hildebrandt B
DIGEST DIS SCI. 2013;58(8):2399-405.

Interventionally implanted port catheter systems for hepatic arterial infusion of chemotherapy in patients with primary liver cancer: a phase II-study (NCT00356161)
Sinn M, Nicolaou A, Ricke J, Podrabsky P, Seehofer D, Gebauer B, Pech M, Neuhaus P, Dörken B, Riess H, Hildebrandt B
BMC GASTROENTEROL. 2013;13:125.

Does long-term survival in patients with pancreatic cancer really exist? Results from the CONKO-001 study
Sinn M, Striefler J, Sinn B, Sallmon D, Bischoff S, Stieler J, Pelzer U, Bahra M, Neuhaus P, Dörken B, Denkert C, Riess H, Oettle H
J SURG ONCOL. 2013;108(6):398-402.

Computed tomography-guided interstitial HDR brachytherapy (CT-HDRBT) of the liver in patients with irresectable intrahepatic cholangiocarcinoma
Schnapauff D, Denecke T, Grieser C, Collettini F, Colletini F, Seehofer D, Sinn M, Banzer J, Lopez-Hänninen E, Hamm B, Wust P, Gebauer B
CARDIOVASC INTER RAD. 2012;35(3):581-7.

Biliary tract cancer: a survey regarding the current oncological daily care practice in Germany
Sinn M, Bischoff S, Nehls O, Pelzer U, von Weizsäcker F, Kubicka S, Stieler J, Caca K, Riess H
ONKOLOGIE. 2012;35(12):755-60.

Letzte Aktualisierung aus dem FIS: 20.04.2024 - 00:38 Uhr